The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: Association with ferritin levels

Sleep Medicine

Volumn 10, Issue 6, 2009, Pages 611-615

  Frauscher, Birgit ^a   Gschliesser, Viola ^a   Brandauer, Elisabeth ^a   El Demerdash, Essam ^a   Kaneider, Matthias ^a   Rücker, Lukas ^a   Poewe, Werner ^a   Högl, Birgit ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Augmentation; Dopamine agonists; IRLS; Iron; Restless legs syndrome (RLS); Risk factor; Treatment; Untreated

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; FERRITIN; GABAPENTIN; IRON; LEVODOPA; LISURIDE; OPIATE DERIVATIVE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONSULTATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; HEALTH CENTER; HUMAN; IDIOPATHIC DISEASE; IRON METABOLISM; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; RESTLESS LEGS SYNDROME; SLEEP DISORDER;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; DOPAMINE AGENTS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERRITINS; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS;

EID: 67349120622     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2008.09.007     Document Type: Article

References (43)

1. Hening W., Walters A.S., Allen R.P., Montplaisir J., Myers A., and Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 5 (2004) 237-246
2. Allen R.P., Walters A.S., Montplaisir J., Hening W., Myers A., Bell T.J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 165 (2005) 1286-1292
3. Högl B., Kiechl S., Willeit H., Saletu M., Frauscher B., Seppi K., et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology 64 (2005) 1920-1924
4. Tison F., Crochard A., Léger D., Bouée S., Lainey E., and El Hasnaoui A. Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT study. Neurology 65 (2005) 239-246
5. Hening W.A. Current guidelines and standards of practice for restless legs syndrome. Am J Med 120 Suppl. 1 (2007) S22-S27
6. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisir J., et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4 (2003) 101-119
7. Garcia-Borreguero D., Allen R.P., Kohnen R., Högl B., Trenkwalder C., Oertel W., et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck institute. Sleep Med 8 (2007) 520-530
8. Allen R.P., and Earley C.J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19 (1996) 205-213
9. Garcia-Borreguero D., Kohnen R., Högl B., Ferini-Strambi L., Hadjigeorgiou G.M., Hornyak M., et al. Validation of the augmentation severity rating scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 8 (2007) 455-463
10. Trenkwalder C., Collado Seidel V., Kazenwadel J., Wetter T.C., Oertel W., Selzer R., et al. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?. Mov Disord 18 (2003) 1184-1189
11. Trenkwalder C., Benes H., Grote L., Happe S., Högl B., Mathis J., et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 22 (2007) 696-703
12. Stiasny-Kolster K., Benes H., Peglau I., Hornyak M., Holinka B., Wessel K., et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 63 (2004) 2272-2279
13. Benes H., Heinrich C.R., Ueberall M.A., and Kohnen R. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 27 (2004) 674-682
14. Winkelman J.W., and Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 5 (2004) 9-14
15. Montplaisir J., Karrasch J., Haan J., and Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 21 (2006) 1627-1635
16. Trenkwalder C., Stiasny-Kolster K., Kupsch A., Oertel W.H., Koester J., and Reess J. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord 21 (2006) 1404-1410
17. Paulus W., and Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol 5 (2006) 878-886
18. Trenkwalder C., Högl B., Benes H., and Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med 9 (2008) 572-574
19. Walters A.S., LeBrocq C., Dhar A., Hening W., Rosen R., Allen R.P., et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4 (2003) 121-132
20. Kohnen R., Oertel W.H., Stiasny-Kolster K., Benes H., and Trenkwalder C. Severity rating of restless legs syndrome: validation of the RLS-6 scales. Sleep 27 Suppl. 1 (2004) A304
21. National Institute of Mental Health (NIMH). Early clinical drug evaluation unit (ECDEU). Clinical Global Impressions. In: Guy W, editor. ECDEU assessment manual for psychopharmacology, rev ed. Rockville, MD: NIMH; 1976.
22. Högl B., Garcia-Borreguero D., Gschliesser V., Cabrero B., Kohnen R., and Allen R.P. On the development of the "structured interview for diagnosis of augmentation during RLS treatment (RLS-SIDA)": first experiences. Sleep Med 6 Suppl. 2 (2005) S158
23. Earley C.J., Connor J.R., Beard J.L., Malecki E.A., Epstein D.K., and Allen R.P. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 54 (2000) 1698-1700
24. Allen R.P., Barker P.B., Wehrl F., Song H.K., and Earley C.J. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 56 (2001) 263-265
25. Connor J.R., Boyer P.J., Menzies S.L., Dellinger B., Allen R.P., Ondo W.G., et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 61 (2003) 304-309
26. Connor J.R., Wang X.S., Patton S.M., Menzies S.L., Troncoso J.C., Earley C.J., et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 62 (2004) 1563-1567
27. Schmidauer C., Sojer M., Seppi K., Stockner H., Högl B., Biedermann B., et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol 58 (2005) 630-634
28. Mizuno S., Mihara T., Miyaoka T., Inagaki T., and Horiguchi J. CSF iron, ferritin and transferrin levels in restless legs syndrome. J Sleep Res 14 (2005) 43-47
29. Winkelmann J., Schormair B., Lichtner P., Ripke S., Xiong L., Jalilzadeh S., et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 39 (2007) 1000-1006
30. Stefansson H., Rye D.B., Hicks A., Petursson H., Ingason A., Thorgeirsson T.E., et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 357 (2007) 639-647
31. Happe S., Vennemann M., Evers S., and Berger K. Treatment wish of individuals with known and unknown restless legs syndrome in the community. J Neurol 255 (2008) 1365-1371
32. Garcia-Borreguero D., Högl B., Ferrini-Strambi L., Hadjigeorgiu G., Hornyak M., de Weerd A., et al. Validation of the augmentation severity rating scale (ASRS): first results from a study of the European restless legs syndrome study group (EURLSSG). Sleep Med 6 Suppl. 2 (2005) S67
33. O'Keeffe S.T., Gavin K., and Lavan J.N. Iron status and restless legs syndrome in the elderly. Age Ageing 23 (1994) 200-203
34. Earley C.J., Heckler D., and Allen R.P. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 5 (2004) 231-235
35. Earley C.J., Horska A., Mohamed M.A., Barker P.B., Beard J.L., and Allen R.P. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med 10 (2009) 206-211
36. RLS Medical Bulletin. Restless legs syndrome. Diagnosis and treatment in primary care. Restless legs syndrome foundation 2008. Available from www.rls.org.
37. Guyatt G.H., Patterson C., Ali M., Singer J., Levine M., Turpie I., et al. Diagnosis of iron-deficiency anemia in the elderly. Am J Med 88 (1990) 205-209
38. Youdim M.B., Sills M.A., Heydorn W.E., Creed G.J., and Jacobowitz D.M. Iron deficiency alters discrete proteins in rat caudate nucleus and nucleus accumbens. J Neurochem 47 (1986) 794-799
39. Nelson C., Erikson K., Pinero D.J., and Beard J.L. In vivo dopamine metabolism is altered in iron-deficient anemic rats. J Nutr 127 (1997) 2282-2288
40. Erikson K.M., Jones B.C., Hess E.J., Zhang Q., and Beard J.L. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharmacol Biochem Behav 69 (2001) 409-418
41. Salvatore M.F., Fisher B., Surgener S.P., Gerhardt G.A., and Rouault T. Neurochemical investigations of dopamine neuronal systems in iron-regulatory protein 2 (IRP-2) knockout mice. Brain Res Mol Brain Res 139 (2005) 341-347
42. Allen R.P., and Earley C.J. The role of iron in restless legs syndrome. Mov Disord 22 Suppl. 18 (2007) S440-448
43. Dean Jr. T., Allen R.P., O'Donnell C.P., and Earley C.J. The effects of dietary iron deprivation on murine circadian sleep architecture. Sleep Med 7 (2006) 634-640